Selective Serotonin Reuptake Inhibitor

Novartis on NME trail

Novartis on NME trail

By Mike Nagle

Novartis is aiming to hunt down its rivals through a pipeline of
truly innovative drugs, measured by increasing numbers of New
Molecular Entities (NMEs) in development.

Spotlight

Follow us

Webinars

Featured Suppliers

All